FIA
IBRX icon

FNY Investment Advisers’s ImmunityBio IBRX Stock Holding History

FNY Investment Advisers’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,000
Closed -$30.7K – 815
2021
Q4 		$30K Hold
5,000
– – 0.02% 292
2021
Q3 		$48K Buy
+5,000
New +$55K 0.02% 357
2021
Q1 		– Sell
-1,000
Closed -$25.9K – 895
2020
Q4 		$13K Sell
1,000
-5,000
-83% -$48.1K ﹤0.01% 564
2020
Q3 		$41K Buy
+6,000
New +$59.8K 0.02% 259
2020
Q2 		– Sell
-10,000
Closed -$28K – 490
2020
Q1 		$28K Buy
+10,000
New +$50.1K 0.02% 263

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FNY Investment Advisers's IBRX Position: Q1 2022 in Review

FNY Investment Advisers sold out of ImmunityBio (IBRX) in Q1 2022, closing a stake of 5,000 shares — an estimated $30.7K sold.

FNY Investment Advisers first reported a position in IBRX in Q1 2020 and held it in 5 quarters. The position peaked at $48K in Q3 2021. 149 funds tracked by Wall St. Rank hold IBRX as of Q1 2022.

  • FNY Investment Advisers reported no remaining ImmunityBio position as of Q1 2022 after selling out during the quarter.
  • FNY Investment Advisers sold 5,000 ImmunityBio shares in Q1 2022, an estimated $30.7K.
  • FNY Investment Advisers first reported a position in ImmunityBio in Q1 2020 and held it in 5 quarters.
  • FNY Investment Advisers's ImmunityBio position peaked at $48K in Q3 2021.
  • 149 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2022.

Based on FNY Investment Advisers's 13F filing for Q1 2022, filed 25 Apr 2022.